Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Tharimmune ( (THAR) ) is now available.
On January 30, 2026, Tharimmune held a virtual special meeting of stockholders, where a quorum representing about 55% of outstanding shares approved six proposals, including the election of two new directors, authorization of share issuances tied to strategic advisor warrants, cryptocurrency-related pre-funded warrants, advisor RSUs, and an increase of 7 million shares under its 2023 Omnibus Equity Incentive Plan. Effective February 1, 2026, former CFTC Commissioner Jill E. Sommers and DRW executive William Wiley, CFA, joined Tharimmune’s board of directors, a move the company framed as strengthening governance and regulatory and capital markets expertise as it advances its Canton Network-focused digital asset strategy and seeks to enhance its role in modernizing financial market infrastructure and driving shareholder value.
More about Tharimmune
Tharimmune, Inc. (NASDAQ: THAR) is a dual-focused company operating as the first publicly traded vehicle leveraging Canton Coin to support the Canton Network’s blockchain-based digitization of traditional financial markets, while also running clinical-stage biotech research and development. The company pursues a differentiated digital asset treasury strategy, including operating as a Super Validator on the Canton Network and investing in applications built on the network to drive institutional blockchain adoption and capital markets utility.
Average Trading Volume: 1,642,272
Technical Sentiment Signal: Buy
Current Market Cap: $193.3M
Find detailed analytics on THAR stock on TipRanks’ Stock Analysis page.